Cited by 114Pancreatic and Hepatic Oncology ResearchGlobal Cancer Incidence and ScreeningPancreatitis Pathology and Treatment

Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals

Open access
Overbeek, Kasper A., Goggins, Michael G., Dbouk, Mohamad, Levink, Iris J.M., Koopmann, Brechtje D.M., Chuidian, Miguel, Konings, Ingrid C.A.W., Paiella, Salvatore +23 more·2022·Gastroenterology

Abstract

BACKGROUND & AIMS: To successfully implement imaging-based pancreatic cancer (PC) surveillance, understanding the timeline and morphologic features of neoplastic progression is key. We aimed to investigate the progression to neoplasia from serial prediagnostic pancreatic imaging tests in high-risk individuals and identify factors associated with successful early detection. METHODS: We retrospectively examined the development of pancreatic abnormalities in high-risk individuals who were diagnosed with PC or underwent pancreatic surgery, or both, in 16 international surveillance programs. RESULTS: Of 2552 high-risk individuals under surveillance, 28 (1%) developed neoplastic progression to PC or high-grade dysplasia during a median follow-up of 29 months after baseline (interquartile range [IQR], 40 months). Of these, 13 of 28 (46%) presented with a new lesion (median size, 15 mm; range 7-57 mm), a median of 11 months (IQR, 8; range 3-17 months) after a prior examination, by which time 10 of 13 (77%) had progressed beyond the pancreas. The remaining 15 of 28 (54%) had neoplastic progression in a previously detected lesion (12 originally cystic, 2 indeterminate, 1 solid), and 11 (73%) had PC progressed beyond the pancreas. The 12 patients with cysts had been monitored for 21 months (IQR, 15 months) and had a median growth of 5 mm/y (IQR, 8 mm/y). Successful early detection (as high-grade dysplasia or PC confined to the pancreas) was associated with resection of cystic lesions (vs solid or indeterminate lesions (odds ratio, 5.388; 95% confidence interval, 1.525-19.029) and small lesions (odds ratio, 0.890/mm; 95% confidence interval 0.812-0.976/mm). CONCLUSIONS: In nearly half of high-risk individuals developing high-grade dysplasia or PC, no prior lesions are detected by imaging, yet they present at an advanced stage. Progression can occur before the next scheduled annual examination. More sensitive diagnostic tools or a different management strategy for rapidly growing cysts are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2021.10.014

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent evidence indicates that pancreas surveillance can downstage pancreatic cancers diagnosed in high-risk individuals, though based on few studies.

    “Recent evidence indicates that pancreas surveillance can downstage pancreatic cancers diagnosed in high-risk individuals (HRIs), although this is based upon only a few studies,12,14-16 with relatively few PDACs diagnosed, and only a small percentage of which were diagnosed with stage I disease.17”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Harinck F, Boersma F, Konings I, et al. Clinicopatho- logical characteristics of pancreatic resection specimens of inherited/familial versus sporadic pancreatic ductal adenocarcinoma. United European Gastroenterol J 2014;2:A74-A75.
  2. Konings IC, Harinck F, Poley JW, et al. Prevalence and progression of cystic pancreatic precursor lesions differ between two groups at high risk of developing pancre- atic cancer. United European Gastroenterol J 2015; 3:A355-A356.

Cited by

Sorted by citations

Authors
Overbeek, K. A., Goggins, M. G., Dbouk, M., Levink, I. J. M., Koopmann, B. D. M., Chuidian, M., Konings, I. C. A. W., Paiella, S., Earl, J., Fockens, P., Gress, T. M., Ausems, M. G. E. M., Poley, J.-W., Thosani, N. C., Half, E., Lachter, J., Stoffel, E. M., Kwon, R. S., Stoita, A., Kastrinos, F., Lucas, A. L., Syngal, S., Brand, R. E., Chak, A., Carrato, A., Vleggaar, F. P., Bartsch, D. K., van Hooft, J. E., Cahen, D. L., Canto, M. I., & Bruno, M. J.
Affiliations
  • Erasmus MC (NL)
  • Johns Hopkins University (US)
  • University of Verona (IT)
  • Instituto Ramón y Cajal de Investigación Sanitaria (ES)
  • Amsterdam University Medical Centers (NL)
  • Philipps University of Marburg (DE)
  • University Medical Center Utrecht (NL)
  • The University of Texas Health Science Center at Houston (US)
  • Rambam Health Care Campus (IL)
  • University of Michigan (US)
  • UNSW Sydney (AU)
  • Columbia University Irving Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Brigham and Women's Hospital (US)
  • University of Pittsburgh Medical Center (US)
  • University Hospitals of Cleveland (US)
  • Universidad de Alcalá (ES)
Corresponding author
Overbeek, Kasper A.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2022-03
Volume
162
Issue
3
Pages
772-785.e4
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3205562473
Cited by
114
References
34
Citations by year
2026: 12 · 2025: 16 · 2024: 32 · 2023: 32 · 2022: 21 · 2021: 1
FWCI
7.83
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc-nd)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • Celgene
  • Bayer
  • Shire
  • AbbVie
  • Medtronic
  • Cook Medical
  • Hope Foundation
  • Abbott Laboratories
  • Boston Scientific Japan
  • Ethicon Endo-Surgery
  • Myriad Genetics
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic cancer, tumor progression, high-grade dysplasia, pancreatic cysts, early detection, high-risk individuals, lesion growth rate, serial imaging
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Metastasis, Pancreas, Pancreatic Cyst, Pancreatic Neoplasms, Precancerous Conditions, Retrospective Studies, Risk Factors, Time Factors, Tomography, X-Ray Computed, Disease Progression, Endosonography, Tumor Burden, Early Detection of Cancer, Watchful Waiting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review